Genotypic Technology Ltd has joined hands with Premier Medical Corporation (PMC) USA for distribution of rapid antigen and antibody kits in India. The company had collaborated with PMC during the first wave of COVID-19 to develop rapid & reliable COVID-19 diagnostic products that will help in screening SARS CoV-2 in less than 20 minutes.
PMC is a reputed manufacturer of rapid tests of various diseases such as malaria, HIV, hepatitis B and C, dengue and syphilis, and has ISO certified world class manufacturing facilities in Gujarat, India.
Despite the scale-up for RTPCR testing of COVID-19, with the staggering number of cases during the second wave, alternate options for rapid testing have been recommended and approved by the MOH. The affordability, portability and speed of testing while using rapid antigen/antibody tests makes them a desirable option in such situation.
Rapid tests enable point-of-care testing of people in less than 20 minutes and help identify those who are likely to be infectious. This can help isolate the patients thus preventing further spread and enabling immediate medical attention.
Rapid antibody tests can be used in deciphering the immune response of a person, determining whether the person has antibodies for SARS CoV-2, typically after COVID-19 infection or vaccination. Rapid antibody tests have also been used in surveillance of SARS-CoV-2 which have helped in identifying undetected chains of disease transmission.
Rapid antigen and antibody kits are CE marked, ICMR approved, and antigen tests have also been listed by WHO under the Emergency Use Listing (EUL) category. These diagnostic products have been benchmarked by Genotypic along with other governmental & reputed private labs for performance, and have shown higher specificity and sensitivity compared to other diagnostic products available in the market, according to the company.
“There is an urgent need to expand point-of-care testing to keep the spread (of COVID) minimal and decrease the waiting time for the results, thus enabling immediate isolation. Antigen cards are ideally suitable for securing educational institutions, workplaces and events. I strongly believe that the rapid test will open gates for the travel and tourism industry to come back to business after the second wave of COVID-19. Genotypic has been working with several technology companies to provide SARS-CoV-2 sequencing solutions to more than 1400 Indian COVID testing labs. We are very pleased to work with PMC on taking this rapid test to India and selected countries across the globe to support the fight against the COVID-19 pandemic,” commented Dr. Raja Mugasimangalam, Founder and CEO, Genotypic Technology in the release.
In addition to developing antigen and antibody kits for COVID-19 we also plan to co-develop novel proteins for differential diagnostics of various infectious diseases such as dengue, chikungunya, zika, ebola and others, said Nilesh Mehta, CEO & President, Premier Medical Corporation, NJ, USA.